How should lamotrigine be initiated and titrated, and how can topiramate be discontinued, in a patient who is only taking 25 mg topiramate for seizure prophylaxis?

Transitioning from Topiramate to Lamotrigine for Seizure Prophylaxis

For a patient taking only 25 mg topiramate daily for seizure prophylaxis, initiate lamotrigine at 25 mg daily for 2 weeks, then increase to 50 mg daily for 2 weeks, followed by weekly increases of 50 mg until reaching a maintenance dose of 300-400 mg daily in divided doses; topiramate can be tapered by taking the capsule every other day for at least 1 week before discontinuation once lamotrigine reaches therapeutic levels. 1

Lamotrigine Initiation and Titration

Standard Titration Schedule:

• Weeks 1-2: 25 mg once daily
• Weeks 3-4: 50 mg daily (can be divided into 25 mg twice daily)
• Week 5: 100 mg daily in divided doses
• Week 6: 150 mg daily in divided doses
• Week 7: 200 mg daily in divided doses
• Week 8 onward: Target 300-400 mg daily in divided doses 2, 3

This gradual titration is critical to minimize the risk of serious rash, including Stevens-Johnson syndrome. Lamotrigine requires several weeks to reach therapeutic levels, which is why overlap with topiramate during the transition is necessary 2.

Important Caveat About Drug Interactions

The titration schedule above assumes the patient is on enzyme-inducing antiepileptic drugs (AEDs). However, since this patient is only on 25 mg topiramate (which is not enzyme-inducing at this low dose), the standard titration applies. If the patient were also taking valproic acid, the lamotrigine doses would need to be reduced by 50% due to significant drug interactions 3.

Topiramate Discontinuation Strategy

At the low dose of 25 mg daily, topiramate discontinuation carries minimal seizure risk, but gradual taper is still recommended:

• Once lamotrigine reaches at least 200 mg daily (approximately week 7), begin topiramate taper
• Take the 25 mg capsule every other day for 1 week
• Then discontinue completely 1

The gradual taper minimizes seizure precipitation risk, though this is primarily a concern at higher topiramate doses (>400 mg/day) 4.

Clinical Monitoring During Transition

Watch for these specific issues:

Lamotrigine-Related:

• Rash: Occurs in 10-17% of patients, typically within the first 8 weeks. Any rash warrants immediate evaluation and potential discontinuation 3
• Common side effects: Dizziness, ataxia, diplopia, somnolence, headache (generally mild and transient) 3, 5
• Seizure control: Monitor seizure frequency throughout transition

Topiramate Withdrawal:

• At 25 mg daily, withdrawal effects are minimal
• Monitor for seizure breakthrough during the first 2-4 weeks after discontinuation
• Patients may experience reversal of topiramate's appetite-suppressing effects (potential weight gain)

Why This Approach Works

Levetiracetam and lamotrigine are the preferred first-line AEDs for brain tumor-related seizures due to efficacy and tolerability, with minimal drug interactions 2. Lamotrigine has excellent antiseizure activity but requires the prolonged titration described above. The overlap period ensures continuous seizure protection while lamotrigine reaches therapeutic levels.

Common Pitfall: Rushing lamotrigine titration to avoid polytherapy increases rash risk substantially. The slow titration is non-negotiable for safety, even though it means 6-8 weeks of dual therapy.

Practical Note: Since topiramate at 25 mg is a very low dose (typical seizure prophylaxis doses are 200-400 mg/day 4), this patient is on minimal effective therapy. The transition to lamotrigine should provide superior seizure control with better long-term tolerability, particularly avoiding topiramate's cognitive side effects that occur even at low doses 6.